BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38466643)

  • 1. Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy.
    Martín M; Yoder R; Salgado R; Del Monte-Millán M; Álvarez EL; Echavarría I; Staley JM; O'Dea AP; Nye LE; Stecklein SR; Bueno C; Jerez Y; Cebollero M; Bueno O; García Saenz JÁ; Moreno F; Bohn U; Gómez H; Massarrah T; Khan QJ; Godwin AK; López-Tarruella S; Sharma P
    Clin Cancer Res; 2024 May; 30(10):2160-2169. PubMed ID: 38466643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.
    Sharma P; Stecklein SR; Yoder R; Staley JM; Schwensen K; O'Dea A; Nye L; Satelli D; Crane G; Madan R; O'Neil MF; Wagner J; Larson KE; Balanoff C; Kilgore L; Phadnis MA; Godwin AK; Salgado R; Khan QJ; O'Shaughnessy J
    JAMA Oncol; 2024 Feb; 10(2):227-235. PubMed ID: 37991778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
    Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
    Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
    Loi S; Drubay D; Adams S; Pruneri G; Francis PA; Lacroix-Triki M; Joensuu H; Dieci MV; Badve S; Demaria S; Gray R; Munzone E; Lemonnier J; Sotiriou C; Piccart MJ; Kellokumpu-Lehtinen PL; Vingiani A; Gray K; Andre F; Denkert C; Salgado R; Michiels S
    J Clin Oncol; 2019 Mar; 37(7):559-569. PubMed ID: 30650045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
    Sharma P; López-Tarruella S; García-Saenz JA; Khan QJ; Gómez HL; Prat A; Moreno F; Jerez-Gilarranz Y; Barnadas A; Picornell AC; Monte-Millán MD; González-Rivera M; Massarrah T; Pelaez-Lorenzo B; Palomero MI; González Del Val R; Cortés J; Fuentes-Rivera H; Morales DB; Márquez-Rodas I; Perou CM; Lehn C; Wang YY; Klemp JR; Mammen JV; Wagner JL; Amin AL; O'Dea AP; Heldstab J; Jensen RA; Kimler BF; Godwin AK; Martín M
    Clin Cancer Res; 2018 Dec; 24(23):5820-5829. PubMed ID: 30061361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).
    Sharma P; Kimler BF; O'Dea A; Nye L; Wang YY; Yoder R; Staley JM; Prochaska L; Wagner J; Amin AL; Larson K; Balanoff C; Elia M; Crane G; Madhusudhana S; Hoffmann M; Sheehan M; Rodriguez R; Finke K; Shah R; Satelli D; Shrestha A; Beck L; McKittrick R; Pluenneke R; Raja V; Beeki V; Corum L; Heldstab J; LaFaver S; Prager M; Phadnis M; Mudaranthakam DP; Jensen RA; Godwin AK; Salgado R; Mehta K; Khan Q
    Clin Cancer Res; 2021 Feb; 27(4):975-982. PubMed ID: 33208340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
    Gluz O; Nitz U; Kolberg-Liedtke C; Prat A; Christgen M; Kuemmel S; Mohammadian MP; Gebauer D; Kates R; Paré L; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Wuerstlein R; Graeser M; Pelz E; Jóźwiak K; Zu Eulenburg C; Kreipe HH; Harbeck N;
    Clin Cancer Res; 2022 Nov; 28(22):4995-5003. PubMed ID: 35797219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
    Park JH; Jonas SF; Bataillon G; Criscitiello C; Salgado R; Loi S; Viale G; Lee HJ; Dieci MV; Kim SB; Vincent-Salomon A; Curigliano G; André F; Michiels S
    Ann Oncol; 2019 Dec; 30(12):1941-1949. PubMed ID: 31566659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
    Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
    Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
    Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
    JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II-III triple negative breast cancer: a retrospective analysis.
    Wang H; Zhang N; Sun Q; Zhao Z; Pang H; Huang X; Zhang R; Kang W; Shan M
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):291. PubMed ID: 38836955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer.
    Van Bockstal MR; Noel F; Guiot Y; Duhoux FP; Mazzeo F; Van Marcke C; Fellah L; Ledoux B; Berlière M; Galant C
    Ann Diagn Pathol; 2020 Dec; 49():151634. PubMed ID: 32987254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
    Sharma P; Barlow WE; Godwin AK; Parkes EE; Knight LA; Walker SM; Kennedy RD; Harkin DP; Logan GE; Steele CJ; Lambe SM; Badve S; Gökmen-Polar Y; Pathak HB; Isakova K; Linden HM; Porter P; Pusztai L; Thompson AM; Tripathy D; Hortobagyi GN; Hayes DF
    J Clin Oncol; 2019 Dec; 37(36):3484-3492. PubMed ID: 31657982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
    Baez-Navarro X; van den Ende NS; Nguyen AH; Sinke R; Westenend P; van Brakel JB; Stobbe C; Westerga J; van Deurzen CHM
    Breast Cancer Res; 2024 Mar; 26(1):41. PubMed ID: 38468323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
    de Jong VMT; Wang Y; Ter Hoeve ND; Opdam M; Stathonikos N; Jóźwiak K; Hauptmann M; Cornelissen S; Vreuls W; Rosenberg EH; Koop EA; Varga Z; van Deurzen CHM; Mooyaart AL; Córdoba A; Groen EJ; Bart J; Willems SM; Zolota V; Wesseling J; Sapino A; Chmielik E; Ryska A; Broeks A; Voogd AC; Loi S; Michiels S; Sonke GS; van der Wall E; Siesling S; van Diest PJ; Schmidt MK; Kok M; Dackus GMHE; Salgado R; Linn SC
    J Clin Oncol; 2022 Jul; 40(21):2361-2374. PubMed ID: 35353548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer.
    Pang J; Zhou H; Dong X; Wang S; Xiao Z
    Clin Breast Cancer; 2021 Dec; 21(6):e681-e687. PubMed ID: 34001439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
    Loibl S; Untch M; Burchardi N; Huober J; Sinn BV; Blohmer JU; Grischke EM; Furlanetto J; Tesch H; Hanusch C; Engels K; Rezai M; Jackisch C; Schmitt WD; von Minckwitz G; Thomalla J; Kümmel S; Rautenberg B; Fasching PA; Weber K; Rhiem K; Denkert C; Schneeweiss A
    Ann Oncol; 2019 Aug; 30(8):1279-1288. PubMed ID: 31095287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study.
    Van Bockstal MR; François A; Altinay S; Arnould L; Balkenhol M; Broeckx G; Burguès O; Colpaert C; Dedeurwaerdere F; Dessauvagie B; Duwel V; Floris G; Fox S; Gerosa C; Hastir D; Jaffer S; Kurpershoek E; Lacroix-Triki M; Laka A; Lambein K; MacGrogan GM; Marchiò C; Martin Martinez MD; Nofech-Mozes S; Peeters D; Ravarino A; Reisenbichler E; Resetkova E; Sanati S; Schelfhout AM; Schelfhout V; Shaaban A; Sinke R; Stanciu-Pop CM; van Deurzen CHM; Van de Vijver KK; Van Rompuy AS; Vincent-Salomon A; Wen HY; Wong S; Bouzin C; Galant C
    Mod Pathol; 2021 Dec; 34(12):2130-2140. PubMed ID: 34218258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.